A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

NCT03463876 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: SHR 1210+apatinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.